Show simple item record

dc.contributor.authorPivovarova, Ekaterina
dc.contributor.authorLidz, Charles W.
dc.date2022-08-11T08:10:17.000
dc.date.accessioned2022-08-23T17:02:27Z
dc.date.available2022-08-23T17:02:27Z
dc.date.issued2016-12-01
dc.date.submitted2016-12-07
dc.identifier.doi10.7191/pib.1107
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44220
dc.description.abstractInstitutional Review Boards (IRBs) play a critical role in research, and assure safety and fairness to participants enrolled in research studies. Multisite studies are often reviewed by multiple IRBs (an IRB review at each site participating in the study), which can slow down study approval, result in duplication of effort, and occasionally produce contradictory decisions by different IRBs. To address these problems, the federal government has promoted the use of single IRBs (referred to as Central IRBs or CIRBs), where a single IRB is responsible for the review of all sites where the research study is conducted. The National Institutes of Health (NIH) has recently announced that beginning in 2017 all research conducted at multiple sites must be reviewed by a CIRB. This CIRB process is new and requires careful study to understand its pitfalls and benefits. As such, UMass Medical School and Columbia University received a (NIH) grant to study how different institutions conduct reviews of research involving multiple sites. A Spanish translation of this publication is available for download.
dc.language.isoen_US
dc.rightsCopyright © University of Massachusetts Medical School.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/
dc.subjectEthics
dc.subjectPolicy
dc.subjectService Systems
dc.subjectIRBs
dc.subjectEthics in Research
dc.subjectCentral IRBs
dc.subjectInstitutional Review Boards
dc.subjectSpanish
dc.titleCentral IRBs: Enhanced Protections for Research Participants [English and Spanish versions]
dc.typeResearch in the Works
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1107&context=pib&unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/pib/vol13/iss10/1
dc.legacy.embargo2016-12-07T00:00:00-08:00
dc.identifier.contextkey9447932
dc.file.descriptionSpanish translation
refterms.dateFOA2022-08-27T05:43:26Z
html.description.abstract<p>Institutional Review Boards (IRBs) play a critical role in research, and assure safety and fairness to participants enrolled in research studies. Multisite studies are often reviewed by multiple IRBs (an IRB review at each site participating in the study), which can slow down study approval, result in duplication of effort, and occasionally produce contradictory decisions by different IRBs. To address these problems, the federal government has promoted the use of single IRBs (referred to as Central IRBs or CIRBs), where a single IRB is responsible for the review of all sites where the research study is conducted. The National Institutes of Health (NIH) has recently announced that beginning in 2017 all research conducted at multiple sites <em>must</em> be reviewed by a CIRB. This CIRB process is new and requires careful study to understand its pitfalls and benefits. As such, UMass Medical School and Columbia University received a (NIH) grant to study how different institutions conduct reviews of research involving multiple sites. A Spanish translation of this publication is available for download.</p>
dc.identifier.submissionpathpib/vol13/iss10/1


Files in this item

Thumbnail
Name:
Lidz_CIRB_RITW.pdf
Size:
556.4Kb
Format:
PDF
Description:
English version
Thumbnail
Name:
1-IRB_centrales___Juntas_de_Re ...
Size:
193.9Kb
Format:
PDF
Description:
IRB centrales -Juntas de Revisión ...

This item appears in the following Collection(s)

Show simple item record

Copyright © University of Massachusetts Medical School.
Except where otherwise noted, this item's license is described as Copyright © University of Massachusetts Medical School.